NYSEMKT: RGNTRegentis Biomaterials Ltd Stock
$7.49-0.01 (-0.13%)
Updated Dec 5, 2025
RGNT Price
$7.49
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$6.95
52 Week High
$7.70
P/E
-1.29x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.22
Operating Cash Flow
-$987k
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RGNT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
RGNT
Ranked#35 of 46
Ranked#35 of 46
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.65 | A | |
| $8.89 | A | |
| $20.23 | A |
Be the first to know about important RGNT news, forecast changes, insider trades & much more!
RGNT News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RGNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RGNT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RGNT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RGNT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RGNT due diligence checks available for Premium users.
Valuation
RGNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.29x
Industry
222.22x
Market
46.7x
RGNT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RGNT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$475.0k
Liabilities
$9.7M
Debt to equity
-0.22
RGNT's short-term liabilities ($9.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGNT's short-term assets ($475.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGNT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RGNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RGNT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Regentis Biomaterials Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.